Literature DB >> 8113817

Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate in vitro binding to dopamine and serotonin transporters under "physiological" conditions.

M Laruelle1, S S Giddings, Y Zea-Ponce, D S Charney, J L Neumeyer, R M Baldwin, R B Innis.   

Abstract

Methyl 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylate ([123I]beta-CIT) is a single photon emission computed tomographic radiotracer for in vivo labeling of dopamine (DA) and serotonin (5-HT) transporters. Single photon emission computed tomographic experiments in nonhuman primates showed that [123I]beta-CIT in vivo binding to DA transporters had a much slower washout than binding to 5-HT transporters. This observation was not predicted from previously published in vitro studies. These studies, performed at 22 degrees C in nonphysiological buffer, reported similar affinity of [125I]beta-CIT for DA and 5-HT transporters. We now report [125I]beta-CIT binding parameters to fresh rat membranes at 22 degrees C and 37 degrees C, in a buffer mimicking the composition of cerebrospinal fluid. At both temperatures, binding to DA transporters was best fit by a two-site model, whereas binding to 5-HT transporters was compatible with one population of sites. At 22 degrees C, [125I]beta-CIT showed similar affinity to high-affinity DA (0.39 nM) and 5-HT transporter sites (0.47 nM). Increasing the incubation temperature from 22 degrees C to 37 degrees C reduced binding to DA transporters by 60%, whereas binding to 5-HT transporters was only marginally affected. In vitro kinetic experiments failed to detect significant differences in on or off rates that could explain the observed in vivo kinetics. These experiments thus failed to explain [125I]beta-CIT in vivo uptake kinetics, suggesting the existence of specific factors affecting the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113817     DOI: 10.1046/j.1471-4159.1994.62030978.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  7 in total

1.  Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.

Authors:  Roger N Gunn; Scott G Summerfield; Cristian A Salinas; Kevin D Read; Qi Guo; Graham E Searle; Christine A Parker; Phil Jeffrey; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-25       Impact factor: 6.200

2.  Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts.

Authors:  R T Malison; S E Best; E A Wallace; E McCance; M Laruelle; S S Zoghbi; R M Baldwin; J S Seibyl; P B Hoffer; L H Price
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

Review 3.  Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.

Authors:  R B Innis
Journal:  Eur J Nucl Med       Date:  1994-01

Review 4.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.

Authors:  Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

5.  Comparison of [123I]beta-CIT and [123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates.

Authors:  B E Scanley; M S al-Tikriti; M S Gandelman; M Laruelle; Y Zea-Ponce; R M Baldwin; S S Zoghbi; P B Hoffer; D S Charney; S Wang
Journal:  Eur J Nucl Med       Date:  1995-01

6.  2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)-phenylthio)benzenamine derivatives as serotonin transporter imaging agents.

Authors:  Ajit K Parhi; Julie L Wang; Shunichi Oya; Seok-Rye Choi; Mei-Ping Kung; Hank F Kung
Journal:  J Med Chem       Date:  2007-12-04       Impact factor: 7.446

7.  Advanced brain dopamine transporter imaging in mice using small-animal SPECT/CT.

Authors:  Miia Pitkonen; Eero Hippeläinen; Mari Raki; Jaan-Olle Andressoo; Arto Urtti; Pekka T Männistö; Sauli Savolainen; Mart Saarma; Kim Bergström
Journal:  EJNMMI Res       Date:  2012-09-29       Impact factor: 3.138

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.